{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:10Z","timestamp":1794017230565,"version":"4.8.0"},"reference-count":71,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153229"],"award-info":[{"award-number":["PJT-153229"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oncopole EMC2"},{"name":"Guerrera Family"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Triple-negative breast cancer (TNBC) is associated with poor prognosis and is mainly treated with chemotherapy-based regimens, often including carboplatin. Resistance to carboplatin is a common clinical issue that is either initially present or develops with treatment. Overcoming this resistance is a significant clinical challenge, which highlights the need for novel therapeutic strategies. We used a pooled short hairpin RNA screening approach with a chemoresistant TNBC patient-derived xenograft (PDX) cell line (PDXC) to identify targets in which knockdown would enhance the efficacy of carboplatin. This screening led to the identification of the ataxia telangiectasia and Rad3-related (ATR) gene as a key therapeutic vulnerability. Inhibiting ATR with BAY1895344 or AZD6738 resensitized carboplatin-resistant PDXCs and PDXs to carboplatin, resulting in an increase in DNA damage and apoptosis. ATR inhibition prevents carboplatin-resistant cells from effectively engaging the S and G2\u2013M checkpoints required for DNA repair, leading to mitotic catastrophe. We further identified that the addition of ATR inhibitors to carboplatin enabled the FOXM1-targeted gene program, leading to premature passage into mitosis. Moreover, targeting PKMYT1, a regulator of cyclin-dependent kinase 1 controlling the G2\u2013M checkpoint, through knockdown or with the novel PKMYT1 inhibitor RP-6306, also enhanced carboplatin efficacy in our TNBC PDXC. Molecular factors associated with the response to the ATR inhibitor\/carboplatin combination included low RNA levels of PKMYT1. These results underscore the pivotal roles of ATR and PKMYT1 in mediating resistance to carboplatin in TNBC and support targeting these pathways to overcome carboplatin resistance in this disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Patients with TNBC are mostly treated with chemotherapy, including carboplatin. Given that patients often develop resistance to carboplatin, finding a way to resensitize them to this agent is paramount. Our work highlights the use of ATR and PKMYT1 inhibitors to resensitize chemoresistant patient-derived models to carboplatin. These studies in patient-derived models establish the basis for novel therapeutic drug combinations to overcome carboplatin resistance in patients with TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0044","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:21:59Z","timestamp":1776090119000},"page":"1092-1108","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3705-1671","authenticated-orcid":false,"given":"Juliet","family":"Guay","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 2 Department of Experimental Medicine, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1256-790X","authenticated-orcid":false,"given":"Hellen","family":"Kuasne","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 3 Rosalind & Morris Goodman Cancer Research Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3045-2317","authenticated-orcid":false,"given":"Catherine","family":"Chabot","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6659-8119","authenticated-orcid":false,"given":"Kathryn","family":"Bozek","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 2 Department of Experimental Medicine, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8445-0348","authenticated-orcid":false,"given":"Yasamin","family":"Majedi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7908-611X","authenticated-orcid":false,"given":"Marguerite","family":"Buchanan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-4383","authenticated-orcid":false,"given":"Adriana","family":"Aguilar-Mahecha","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-7160","authenticated-orcid":false,"given":"Eric","family":"Bareke","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 4 Department of Human Genetic, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9732-6081","authenticated-orcid":false,"given":"Benjamin","family":"Ulmer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3240-8989","authenticated-orcid":false,"given":"Tim","family":"Kong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 3 Rosalind & Morris Goodman Cancer Research Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 5 Department of Biochemistry, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-913X","authenticated-orcid":false,"given":"Kangning","family":"Yang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 3 Rosalind & Morris Goodman Cancer Research Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 5 Department of Biochemistry, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0201-3468","authenticated-orcid":false,"given":"Minyan","family":"Liao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 3 Rosalind & Morris Goodman Cancer Research Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 5 Department of Biochemistry, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8658-7779","authenticated-orcid":false,"given":"Oluwadara","family":"Elebute","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0678-3708","authenticated-orcid":false,"given":"Ruining","family":"Guo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-0090","authenticated-orcid":false,"given":"Anie","family":"Monast","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 3 Rosalind & Morris Goodman Cancer Research Institute, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6398-9593","authenticated-orcid":false,"given":"Genevi\u00e8ve","family":"Morin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 3 Rosalind & Morris Goodman Cancer Research Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 4 Department of Human Genetic, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2838-4726","authenticated-orcid":false,"given":"Sidong","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 3 Rosalind & Morris Goodman Cancer Research Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 5 Department of Biochemistry, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-606X","authenticated-orcid":false,"given":"Morag","family":"Park","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 3 Rosalind & Morris Goodman Cancer Research Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 5 Department of Biochemistry, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 6 Department of Oncology, , Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-5410","authenticated-orcid":false,"given":"Mark","family":"Basik","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 1 Lady Davis Institute, , Montreal, Canada."},{"id":[{"id":"https:\/\/ror.org\/01pxwe438","id-type":"ROR","asserted-by":"publisher"}],"name":"McGill University 6 Department of Oncology, , Montreal, Canada."},{"name":"7Department of Surgery, McGill University, Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026051201332893000_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"2026051201332893000_bib2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00432-018-2644-2","article-title":"Patterns of breast cancer relapse in accordance to biological subtype","volume":"144","author":"Ignatov","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026051201332893000_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"2026051201332893000_bib4","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00432-022-04189-6","article-title":"Triple negative breast cancer: approved treatment options and their mechanisms of action","volume":"149","author":"Mandapati","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026051201332893000_bib5","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol"},{"key":"2026051201332893000_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The drug-resistance mechanisms of five platinum-based antitumor agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026051201332893000_bib7","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1038\/s41598-021-82780-6","article-title":"The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers","volume":"11","author":"Moens","year":"2021","journal-title":"Sci Rep"},{"key":"2026051201332893000_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026051201332893000_bib9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.aap9346","article-title":"An intrinsic S\/G2 checkpoint enforced by ATR","volume":"361","author":"Saldivar","year":"2018","journal-title":"Science"},{"key":"2026051201332893000_bib10","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents","volume":"278","author":"Xiao","year":"2003","journal-title":"J Biol Chem"},{"key":"2026051201332893000_bib11","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"key":"2026051201332893000_bib12","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2026051201332893000_bib13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026051201332893000_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"2026051201332893000_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","article-title":"Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours","volume":"125","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"2026051201332893000_bib16","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026051201332893000_bib17","doi-asserted-by":"crossref","first-page":"zcac045","DOI":"10.1093\/narcan\/zcac045","article-title":"ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe","volume":"5","author":"Heyza","year":"2023","journal-title":"NAR Cancer"},{"key":"2026051201332893000_bib18","doi-asserted-by":"crossref","first-page":"167448","DOI":"10.1016\/j.bbadis.2024.167448","article-title":"SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells","volume":"1870","author":"K\u00f6nig","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026051201332893000_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4615-5371-7_18","article-title":"Myt1: a Wee1-type kinase that phosphorylates Cdc2 on residue Thr14","volume":"3","author":"Fattaey","year":"1997","journal-title":"Prog Cell Cycle Res"},{"key":"2026051201332893000_bib20","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/MCB.00891-10","article-title":"Inhibitory phosphorylation of cyclin-dependent kinase 1 as a compensatory mechanism for mitosis exit","volume":"31","author":"Chow","year":"2011","journal-title":"Mol Cell Biol"},{"key":"2026051201332893000_bib21","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1038\/onc.2012.504","article-title":"The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery","volume":"32","author":"Chow","year":"2013","journal-title":"Oncogene"},{"key":"2026051201332893000_bib22","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/0008-5472.CAN-23-4130","article-title":"Low-molecular weight cyclin E confers a vulnerability to PKMYT1 inhibition in triple-negative breast cancer","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"key":"2026051201332893000_bib23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-23-0564","article-title":"PKMYT1 is a marker of treatment response and a therapeutic target for CDK4\/6 inhibitor-resistance in ER+ breast cancer","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2026051201332893000_bib24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/neuonc\/noad252","article-title":"Abrogation of the G2\/M checkpoint as a chemosensitization approach for alkylating agents","volume":"26","author":"Lang","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026051201332893000_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41392-025-02250-7","article-title":"PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026051201332893000_bib26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nprot.2016.174","article-title":"Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens","volume":"12","author":"Liu","year":"2017","journal-title":"Nat Protoc"},{"key":"2026051201332893000_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"2026051201332893000_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"2026051201332893000_bib29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/0008-5472.CAN-19-1108","article-title":"CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers","volume":"80","author":"Kong","year":"2020","journal-title":"Cancer Res"},{"key":"2026051201332893000_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"2026051201332893000_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol"},{"key":"2026051201332893000_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev"},{"key":"2026051201332893000_bib33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0960-9822(00)00447-4","article-title":"Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice","volume":"10","author":"de Klein","year":"2000","journal-title":"Curr Biol"},{"key":"2026051201332893000_bib34","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","article-title":"Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint","volume":"14","author":"Liu","year":"2000","journal-title":"Genes Dev"},{"key":"2026051201332893000_bib35","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1","volume":"21","author":"Zhao","year":"2001","journal-title":"Mol Cell Biol"},{"key":"2026051201332893000_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cub.2005.11.066","article-title":"Rapid PIKK-dependent release of Chk1 from chromatin promotes the DNA-damage checkpoint response","volume":"16","author":"Smits","year":"2006","journal-title":"Curr Biol"},{"key":"2026051201332893000_bib37","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"2026051201332893000_bib38","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1242\/jcs.053702","article-title":"Human RPA phosphorylation by ATR stimulates DNA synthesis and prevents ssDNA accumulation during DNA-replication stress","volume":"122","author":"Vassin","year":"2009","journal-title":"J Cell Sci"},{"key":"2026051201332893000_bib39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.dnarep.2014.04.008","article-title":"DNA-PK phosphorylation of RPA32 Ser4\/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe","volume":"21","author":"Ashley","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"2026051201332893000_bib40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ncb1446","article-title":"Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway","volume":"8","author":"Ziv","year":"2006","journal-title":"Nat Cell Biol"},{"key":"2026051201332893000_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"gammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"2026051201332893000_bib42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.neo.2018.03.003","article-title":"Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer","volume":"20","author":"Jin","year":"2018","journal-title":"Neoplasia"},{"key":"2026051201332893000_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"S\u00f8rensen","year":"2003","journal-title":"Cancer Cell"},{"key":"2026051201332893000_bib44","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.277.5331.1497","article-title":"Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25","volume":"277","author":"Sanchez","year":"1997","journal-title":"Science"},{"key":"2026051201332893000_bib45","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/sj.onc.1207528","article-title":"Cell death by mitotic catastrophe: a molecular definition","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene"},{"key":"2026051201332893000_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/cdd.2008.182","article-title":"Mitotic catastrophe is the predominant response to histone acetyltransferase depletion","volume":"16","author":"Ha","year":"2009","journal-title":"Cell Death Differ"},{"key":"2026051201332893000_bib47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/cancers11030355","article-title":"Uniform widespread nuclear phosphorylation of histone H2AX is an indicator of lethal DNA replication stress","volume":"11","author":"Moeglin","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026051201332893000_bib48","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/bioinformatics\/btq466","article-title":"ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments","volume":"26","author":"Lachmann","year":"2010","journal-title":"Bioinformatics"},{"key":"2026051201332893000_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1083\/jcb.200812045","article-title":"The decision to enter mitosis: feedback and redundancy in the mitotic entry network","volume":"185","author":"Lindqvist","year":"2009","journal-title":"J Cell Biol"},{"key":"2026051201332893000_bib50","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.devcel.2010.02.013","article-title":"Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis","volume":"18","author":"Gavet","year":"2010","journal-title":"Dev Cell"},{"key":"2026051201332893000_bib51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/MCB.17.2.571","article-title":"The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex","volume":"17","author":"Liu","year":"1997","journal-title":"Mol Cell Biol"},{"key":"2026051201332893000_bib52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.270.5233.86","article-title":"Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15","volume":"270","author":"Mueller","year":"1995","journal-title":"Science"},{"key":"2026051201332893000_bib53","first-page":"111694","article-title":"WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry","volume":"819\u2013820","author":"Elbaek","year":"2020","journal-title":"Mutat Res"},{"key":"2026051201332893000_bib54","doi-asserted-by":"crossref","first-page":"22300","DOI":"10.1074\/jbc.272.35.22300","article-title":"Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity","volume":"272","author":"Booher","year":"1997","journal-title":"J Biol Chem"},{"key":"2026051201332893000_bib55","doi-asserted-by":"crossref","first-page":"25277","DOI":"10.1074\/jbc.C300126200","article-title":"Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate","volume":"278","author":"Nakajima","year":"2003","journal-title":"J Biol Chem"},{"key":"2026051201332893000_bib56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ncb741","article-title":"Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2\/M-phase transition","volume":"4","author":"Okumura","year":"2002","journal-title":"Nat Cell Biol"},{"key":"2026051201332893000_bib57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/emboj.2012.329","article-title":"MEK1 inactivates Myt1 to regulate Golgi membrane fragmentation and mitotic entry in mammalian cells","volume":"32","author":"Villeneuve","year":"2013","journal-title":"EMBO J"},{"key":"2026051201332893000_bib58","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.cub.2010.02.050","article-title":"A two-step inactivation mechanism of Myt1 ensures CDK1\/cyclin B activation and meiosis I entry","volume":"20","author":"Ruiz","year":"2010","journal-title":"Curr Biol"},{"key":"2026051201332893000_bib59","doi-asserted-by":"crossref","first-page":"116019","DOI":"10.1016\/j.celrep.2025.116019","article-title":"The mitotic ATR-Chk1 pathway promotes CDK1 activity for faithful chromosome segregation","volume":"44","author":"Joo","year":"2025","journal-title":"Cell Rep"},{"key":"2026051201332893000_bib60","doi-asserted-by":"crossref","first-page":"10251","DOI":"10.1021\/acs.jmedchem.2c00552","article-title":"Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306","volume":"65","author":"Szychowski","year":"2022","journal-title":"J Med Chem"},{"key":"2026051201332893000_bib61","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"key":"2026051201332893000_bib62","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"2026051201332893000_bib63","doi-asserted-by":"crossref","first-page":"190156","DOI":"10.1098\/rsob.190156","article-title":"A consensus set of genetic vulnerabilities to ATR inhibition","volume":"9","author":"Hustedt","year":"2019","journal-title":"Open Biol"},{"key":"2026051201332893000_bib64","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"key":"2026051201332893000_bib65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2026051201332893000_bib66","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s42003-020-1042-x","article-title":"Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors","volume":"3","author":"Savage","year":"2020","journal-title":"Commun Biol"},{"key":"2026051201332893000_bib67","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026051201332893000_bib68","doi-asserted-by":"crossref","first-page":"15410","DOI":"10.3390\/ijms232315410","article-title":"Revisiting the anti-cancer toxicity of clinically approved platinating derivatives","volume":"23","author":"Forgie","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026051201332893000_bib69","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1042\/BJ20141063","article-title":"A stable RNA G-quadruplex within the 5\u2032-UTR of Arabidopsis thaliana ATR mRNA inhibits translation","volume":"467","author":"Kwok","year":"2015","journal-title":"Biochem J"},{"key":"2026051201332893000_bib70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13062-021-00313-7","article-title":"A link between mitotic defects and mitotic catastrophe: detection and cell fate","volume":"16","author":"Sazonova","year":"2021","journal-title":"Biol Direct"},{"key":"2026051201332893000_bib71","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.277.5331.1501","article-title":"Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216","volume":"277","author":"Peng","year":"1997","journal-title":"Science"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0044\/3769619\/crc-25-0044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1092\/3793557\/crc-25-0044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1092\/3793557\/crc-25-0044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:33:51Z","timestamp":1778564031000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/5\/1092\/785149\/ATR-and-PKMYT1-Inhibition-Resensitizes-a-Subset-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0044","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32702102","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702057","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702069","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702027","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702114","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702075","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702087","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702144","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702033","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702099","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702045","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702132","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702093","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702150","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702063","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702081","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702117","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702105","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702129","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702135","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702123","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702048","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702141","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702054","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702066","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702111","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702078","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702084","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702096","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702030","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702090","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702039","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702138","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.07.629892","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.8541983","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}